No Picture
Boston Cambridge Biotech Trending News

Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Jan. 20, 2022 /PRNewswire/ — Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will advance into a Phase 2-3 registrational study through the […]

No Picture
Boston Cambridge Biotech Trending News

Syndax Announces Presentation at B. Riley Securities’ 2022 Oncology Conference

WALTHAM, Mass.: WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ — Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members […]

No Picture
Boston Cambridge Biotech Trending News

FDA+ roundup: FDA’s neuroscience deputy departs amid ongoing Aduhelm investigations; Califf on the ropes?

Amid increased scrutiny into the close ties between FDA and Biogen prior to the controversial accelerated approval of Aduhelm, the deputy director of the FDA’s office of neuroscience has called it quits after more than […]

No Picture
Boston Cambridge Biotech Trending News

Biogen thinks a CMS-mandated trial is a death sentence. Others see a chance to change the future of Alzheimer’s trials

Biogen has gone full blitz since Medicare announced it would only cover its new Alzheimer’s drug when used in clinical trials, accusing the agency of discriminating against Alzheimer’s patients and trying to get physicians to […]

No Picture
Boston Cambridge Biotech Trending News

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Jan. 18, 2022 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish […]

No Picture
Boston Cambridge Biotech Trending News

MarketingRx roundup: Aduhelm can’t get traction with docs; Pfizer presses vaccine effort during NFL playoffs

While much of the pharma industry’s attention pivoted to CMS’ preliminary decision last week to only cover Biogen’s controversial Alzheimer’s drug Aduhelm in clinical trials and its effect on prescribing, neurologists were already hesitant. Spherix […]